RZ-358 is a Monoclonal Antibody owned by Rezolute, and is involved in 7 clinical trials, of which 5 were completed, 1 is ongoing, and 1 is planned.

RZ-358 is an antagonist (deactivator) of the insulin receptor. Inhibition of the insulin receptor mitigates the insulin-induced hypoglycemia by inhibiting the downstream signaling of insulin.

The revenue for RZ-358 is expected to reach a total of $911m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the RZ-358 NPV Report.

RZ-358 was originated by XOMA and is currently owned by Rezolute. XOMA is the other company associated in development or marketing of RZ-358.

RZ-358 Overview

RZ-358 (XOMA-358) is under development for the treatment of hyperinsulinemic hypoglycemia post gastric bypass surgery, and hypoglycemia associated with congenital hyperinsulinism. The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

XOMA Overview

XOMA, formerly XOMA Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, XMetA, X213 (formerly LFA 102) and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 is an allosteric inhibitor of prolactin action. XOMA has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. XOMA is headquartered in Berkeley, California, the US.

The company reported revenues of (US Dollars) US$38.2 million for the fiscal year ended December 2021 (FY2021), an increase of 29.9% over FY2020. In FY2021, the company’s operating margin was 45.1%, compared to an operating margin of 42.3% in FY2020. In FY2021, the company recorded a net margin of 41.4%, compared to a net margin of 45.3% in FY2020. The company reported revenues of US$0.5 million for the third quarter ended September 2022, a decrease of 54.1% over the previous quarter.

Quick View – RZ-358

Report Segments
  • Innovator
Drug Name
  • RZ-358
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Metabolic Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.